Delcath Systems
Delcath Systems Inc. is a commercial-stage interventional oncology company focused on advancing treatment options for patients with primary and metastatic liver cancers. With a commitment to innovative and minimally-invasive therapies, Delcath aims to lead the field in providing targeted solutions for individuals affected by liver metastases.
The company's FDA-approved treatment, HEPZATO KIT, is specifically designed for adult patients with metastatic Uveal Melanoma, while its European counterpart, CHEMOSAT, offers a similar approach for hepatic delivery. In a landscape where liver cancers impact 1.2 million people globally each year, Delcath is dedicated to pioneering new pathways for effective treatment.
Generated from the website
You might also like
Partial Data by Foursquare.